Amgen Inc. AMGN shares are trading close to its 52-week high on Wednesday after the company reported better-than-expected ...
With the first Phase 3 data expected for Amgen’s MariTide next year, analysts are looking for evidence that the GLP-1 ...
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (95.8%): drugs for treating cancer, metabolic disorders, bone ...
Amgen (NasdaqGS:AMGN) announced a new collaboration with the National Organization for Rare Disorders to speed rare ...
By Deena Beasley Nov 3 (Reuters) - Amgen on Tuesday said third-quarter sales rose 8%, led by demand for cholesterol drug Repatha and newer medicines Imdelltra for lung cancer and rare disease therapy ...
In Q3, Amgen reported adjusted EPS of $6.45, up from $5.64 in the same quarter last year. This result came in well above ...
Amgen appears safe, but the current valuation above $450/share may prove expensive by Q3 2026. Click here to read an analysis of AMGN stock now.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results